Advanced in Peripheral T-Cell Lymphoma

Dehui H. Zou

288 Nanjing Road, 
Tianjin, CN 
Advanced in Peripheral T-Cell Lymphoma
288 Nanjing Road, 
Tianjin, CN 
OverviewLocationsClinical Research

Overview

Dehui Zou practices in Tianjin, China. Zou is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Mantle Cell Lymphoma (MCL), Waldenstrom Macroglobulinemia, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 173 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Peripheral T-Cell Lymphoma.

Locations

288 Nanjing Road, Tianjin, China
Other Locations
No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

CNCT19 Following Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Aggressive B-cell Lymphoma
CNCT19 Following Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Aggressive B-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 13, 2025
Intervention Type: Biological, Drug
Study Drugs: CNCT19 4-1BB Anti-CD19 CAR-T Cells, Gemcitabine, Busulfan, Melphalan
Study Phase: Phase 1/Phase 2
A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drug: C-CAR066
Study Phase: Phase 1
A Single Cohort, Open-label, Multicenter, Dose-escalation Study of Safety and Efficacy of BZ019 for Adult CD19 Positive Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
A Single Cohort, Open-label, Multicenter, Dose-escalation Study of Safety and Efficacy of BZ019 for Adult CD19 Positive Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Enrollment Status: Unknown
Publish Date: March 17, 2020
Intervention Type: Biological
Study Drug: BZ019
Study Phase: Phase 1
View 2 Less Clinical Trials

173 Total Publications

Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma.
Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma.
Journal: Cancers
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zou's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile